Solanezumab is an anti-amyloid beta monoclonal antibody being investigated as a potential treatment to delay the progression of mild to moderate Alzheimer’s disease.
The trials, called EXPEDITION and EXPEDITION 2, will each include a treatment period that lasts 18 months and are expected to enroll a total of 2,000 patients age 55 and over from 16 countries.
Patients or caregivers interested in learning how to enroll in EXPEDITION trials should visit www.clinicaltrials.gov or call 1-877-CTLilly (1-877-285-4559).<헬스코리아뉴스>
저작권자 © 헬스코리아뉴스 무단전재 및 재배포 금지